Global's Top Penny Stocks For September 2026

The global markets have faced a challenging week, with major U.S. stock indexes closing lower as geopolitical tensions in the Middle East drove oil prices higher and fueled inflation concerns. In such volatile conditions, investors often seek opportunities that offer potential growth at lower price points. Penny stocks, though an older term, remain relevant for those interested in smaller or newer companies that may provide underappreciated growth prospects. When these stocks are backed by solid financial health and fundamentals, they can present intriguing investment opportunities despite the broader market uncertainties.

We'll examine a selection from our screener results.

Ajman Bank PJSC (DFM:AJMANBANK)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ajman Bank PJSC offers a range of banking products and services to individuals, businesses, and government entities in the United Arab Emirates, with a market capitalization of AED3.97 billion.

Operations: Ajman Bank PJSC generates its revenue primarily from Wholesale Banking (AED509.65 million), Consumer Banking (AED274.71 million), and Treasury operations (AED182.11 million).

Market Cap: AED3.97B

Ajman Bank PJSC, with a market cap of AED3.97 billion, demonstrates a mixed investment profile. The bank's earnings have grown significantly over the past five years at 31.9% annually, though recent growth has decelerated to 16.5%. Despite having high-quality earnings and an attractive price-to-earnings ratio of 7.9x compared to the AE market average of 10.7x, it faces challenges with a high level of bad loans at 5.9% and low allowance for these loans at 48%. Recent results show stable net interest income growth and consistent basic earnings per share from continuing operations year-over-year.

• Unlock comprehensive insights into our analysis of Ajman Bank PJSC stock in this financial health report.
• Learn about Ajman Bank PJSC's historical performance here.

Akfen Gayrimenkul Yatirim Ortakligi (IBSE:AKFGY)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Akfen Gayrimenkul Yatirim Ortakligi A.S., with a market cap of TRY11.05 billion, operates as a real estate investment company following its restructuring from Aksel Tourism Investments and Management Inc.

Operations: The company's revenue primarily comes from its real estate investments, totaling TRY1.73 billion.

Market Cap: TRY11.05B

Akfen Gayrimenkul Yatirim Ortakligi A.S., with a market cap of TRY11.05 billion, presents an intriguing yet complex investment profile. The company has reduced its debt to equity ratio significantly over five years, now at 12.4%, and its short-term assets surpass short-term liabilities by TRY4.1 billion. However, long-term liabilities remain uncovered by these assets, posing financial risks. Recent earnings show a decline in net income and profit margins compared to the previous year, impacted by large one-off items totaling TRY2.1 billion. Despite these challenges, the company's stock trades substantially below estimated fair value and maintains stable weekly volatility.

• Click here and access our complete financial health analysis report to understand the dynamics of Akfen Gayrimenkul Yatirim Ortakligi.
• Gain insights into Akfen Gayrimenkul Yatirim Ortakligi's past trends and performance with our report on the company's historical track record.

Guangzhou Innogen Pharmaceutical Group (SEHK:2591)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Guangzhou Innogen Pharmaceutical Group Co., Ltd focuses on the research, development, and commercialization of pharmaceutical products, with a market cap of approximately HK$1.82 billion.

Operations: The company's revenue is primarily derived from the sales of pharmaceutical products, totaling CN¥153.28 million.

Market Cap: HK$1.82B

Guangzhou Innogen Pharmaceutical Group Co., Ltd, with a market cap of HK$1.82 billion, focuses on pharmaceutical development and commercialization. Despite being unprofitable, its revenue grew to CN¥153.28 million, supported by a strong cash position that surpasses its debt levels. Recent developments include securing ANVISA's GMP certification for Efsubaglutide alfa production in Brazil, enhancing global market access and strategic expansion into South America. However, the company's management team is relatively inexperienced with an average tenure of 0.6 years. The stock remains volatile but trades significantly below estimated fair value with no recent shareholder dilution.

• Take a closer look at Guangzhou Innogen Pharmaceutical Group's potential here in our financial health report.
• Gain insights into Guangzhou Innogen Pharmaceutical Group's outlook and expected performance with our report on the company's earnings estimates.

Key Takeaways

• Get an in-depth perspective on all 3,596 Global Penny Stocks by using our screener here.
• Curious About Other Options? Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com